Cobolimab

考伯利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameCobolimab
Drug Alias NameTSR-022WBP 296AGSK-4069889
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLiver Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnaptysbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcUniversity Of Hawaii
Inactive CompaniesTesaro Inc
Active IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungLiver Neoplasms +[13] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A